S&P 500   4,593.46 (+0.56%)
DOW   36,237.26 (+0.80%)
QQQ   389.68 (+0.22%)
AAPL   191.08 (+0.59%)
MSFT   374.57 (-1.15%)
META   325.27 (-0.57%)
GOOGL   131.60 (-0.70%)
AMZN   147.00 (+0.62%)
TSLA   238.09 (-0.83%)
NVDA   467.36 (-0.07%)
NIO   7.20 (-0.96%)
BABA   73.89 (-1.32%)
AMD   121.10 (-0.05%)
T   16.70 (+0.78%)
F   10.55 (+2.83%)
MU   75.75 (-0.49%)
CGC   0.62 (+11.07%)
GE   122.91 (+0.91%)
DIS   92.32 (-0.40%)
AMC   6.88 (+3.46%)
PFE   28.80 (-5.48%)
PYPL   59.53 (+3.33%)
XOM   102.77 (+0.03%)
S&P 500   4,593.46 (+0.56%)
DOW   36,237.26 (+0.80%)
QQQ   389.68 (+0.22%)
AAPL   191.08 (+0.59%)
MSFT   374.57 (-1.15%)
META   325.27 (-0.57%)
GOOGL   131.60 (-0.70%)
AMZN   147.00 (+0.62%)
TSLA   238.09 (-0.83%)
NVDA   467.36 (-0.07%)
NIO   7.20 (-0.96%)
BABA   73.89 (-1.32%)
AMD   121.10 (-0.05%)
T   16.70 (+0.78%)
F   10.55 (+2.83%)
MU   75.75 (-0.49%)
CGC   0.62 (+11.07%)
GE   122.91 (+0.91%)
DIS   92.32 (-0.40%)
AMC   6.88 (+3.46%)
PFE   28.80 (-5.48%)
PYPL   59.53 (+3.33%)
XOM   102.77 (+0.03%)
S&P 500   4,593.46 (+0.56%)
DOW   36,237.26 (+0.80%)
QQQ   389.68 (+0.22%)
AAPL   191.08 (+0.59%)
MSFT   374.57 (-1.15%)
META   325.27 (-0.57%)
GOOGL   131.60 (-0.70%)
AMZN   147.00 (+0.62%)
TSLA   238.09 (-0.83%)
NVDA   467.36 (-0.07%)
NIO   7.20 (-0.96%)
BABA   73.89 (-1.32%)
AMD   121.10 (-0.05%)
T   16.70 (+0.78%)
F   10.55 (+2.83%)
MU   75.75 (-0.49%)
CGC   0.62 (+11.07%)
GE   122.91 (+0.91%)
DIS   92.32 (-0.40%)
AMC   6.88 (+3.46%)
PFE   28.80 (-5.48%)
PYPL   59.53 (+3.33%)
XOM   102.77 (+0.03%)
S&P 500   4,593.46 (+0.56%)
DOW   36,237.26 (+0.80%)
QQQ   389.68 (+0.22%)
AAPL   191.08 (+0.59%)
MSFT   374.57 (-1.15%)
META   325.27 (-0.57%)
GOOGL   131.60 (-0.70%)
AMZN   147.00 (+0.62%)
TSLA   238.09 (-0.83%)
NVDA   467.36 (-0.07%)
NIO   7.20 (-0.96%)
BABA   73.89 (-1.32%)
AMD   121.10 (-0.05%)
T   16.70 (+0.78%)
F   10.55 (+2.83%)
MU   75.75 (-0.49%)
CGC   0.62 (+11.07%)
GE   122.91 (+0.91%)
DIS   92.32 (-0.40%)
AMC   6.88 (+3.46%)
PFE   28.80 (-5.48%)
PYPL   59.53 (+3.33%)
XOM   102.77 (+0.03%)

Wave Life Sciences Stock Price, News & Analysis (NASDAQ:WVE)

$5.51
+0.20 (+3.77%)
(As of 02:50 PM ET)
Compare
Today's Range
$5.27
$5.69
50-Day Range
$5.12
$6.02
52-Week Range
$3.15
$7.12
Volume
274,275 shs
Average Volume
367,550 shs
Market Capitalization
$545.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.40

Wave Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
30.1% Upside
$7.40 Price Target
Short Interest
Bearish
3.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

495th out of 948 stocks

Pharmaceutical Preparations Industry

235th out of 449 stocks


WVE stock logo

About Wave Life Sciences Stock (NASDAQ:WVE)

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

WVE Stock Price History

WVE Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
WAVE Life Sciences Ltd WVE
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Wave Life Sciences (NASDAQ: WVE)
RBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.40
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+39.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-161,820,000.00
Pretax Margin
-99.39%

Debt

Sales & Book Value

Annual Sales
$3.65 million
Book Value
($0.41) per share

Miscellaneous

Free Float
68,248,000
Market Cap
$525.96 million
Optionable
Optionable
Beta
-1.08
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Paul B. Bolno M.B.A. (Age 49)
    M.D., President, CEO & Director
    Comp: $1.1M
  • Mr. Kyle B. Moran CFA (Age 52)
    CFO & Principal Accounting Officer
    Comp: $677.87k
  • Dr. Chandra Vargeese Ph.D. (Age 62)
    CTO & Head of Platform Discovery Sciences
    Comp: $710.05k
  • Kate Rausch
    Head of Investor Relations
  • Ms. Linda Rockett J.D.
    General Counsel
  • Dr. Christopher Francis Ph.D. (Age 45)
    Senior VP of Corporate Development & Head of Emerging Areas
    Comp: $493.13k
  • Ms. Daryn Lewis
    Senior VP & Head of Human Resources
  • Dr. Sridhar Vaddeboina Ph.D.
    Senior Vice President of Chemistry, Manufacturing & Controls
  • Ms. Anne-Marie Li-Kwai-Cheung
    Chief Development Officer
  • Dr. Hsiu-Chiung Yang Ph.D.
    Senior Vice President of Translational Medicine














WVE Stock Analysis - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2023?

Wave Life Sciences' stock was trading at $7.00 on January 1st, 2023. Since then, WVE shares have decreased by 18.7% and is now trading at $5.69.
View the best growth stocks for 2023 here
.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our WVE earnings forecast
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, November, 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.21. The firm had revenue of $49.21 million for the quarter, compared to analysts' expectations of $28.81 million.

What ETF holds Wave Life Sciences' stock ?

iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M28 Capital Management LP (7.11%), 683 Capital Management LLC (5.91%), Kynam Capital Management LP (3.97%), Adage Capital Partners GP L.L.C. (3.82%), Primecap Management Co. CA (3.82%) and Laurion Capital Management LP (0.88%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:WVE) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -